Skip to content
DataLookout
Menu

NCT05681039

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 2 years later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 19 versions: 8 with changes below, 11 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Nov 1, 2026 to Nov 1, 2028
    • Eligibility criteria expanded, about 56 words
    • Study description revised
  2. Minor Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised
    v18
  3. Minor Site contact updatedv16
  4. Notable Primary completion date: Nov 1, 2025 to Nov 1, 2026
    • Site contact updated
    v15
  5. Notable Primary completion date: Nov 1, 2024 to Nov 1, 2025v10
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 30, 2023 to Jun 2, 2023
    • Site details revised
    v4
  2. Notable Primary endpoint revisedv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

The major pathological response rate after neoadjuvant atezolizumab and tiragolumab.
Timeframe: through study completion; an average of 1 year.

Arms and interventions

Neoadjuvant and AdjuvantExperimental

Drugs: Tiragolumab, Atezolizumab

Behavioral: Standard of Care, Questionnaires

Radiation: Cisplatin, Carboplatin

Sites

1 site in 1 country

  • M D Anderson Cancer CenterHouston, Texas, United States